Quantitative digital assessment of MGMT immunohistochemical expression in glioblastoma tissue
Authors:
- 20 January 2011
- journal article
- conference paper
- Published by Springer Nature in Brain Tumor Pathology
- Vol. 28 (1) , 25-31
Abstract
Recent reports have suggested an important clinical role for hypermethylation of the O6-methylguanine-DNA-methyltransferase (MGMT) promoter in patients with glioblastomas. Whether MGMT protein expression is correlated with promoter hypermethylation and patient outcomes, however, has not been elucidated. Here we describe a quantitative digital method for assessment of MGMT-specific immunostaining, and analyze the relationship between expression levels and methylation status of the MGMT promoter. We investigated 46 tumors from patients who received a diagnosis of glioblastoma or gliosarcoma. Immunohistochemistry with anti-MGMT antibody and methylation-specific PCR using bisulfite-modified tumor DNA were performed. The digital assessment method used image-analysis software to determine a digital MGMT staining index, and the results were compared with those obtained via conventional visual assessments. The digital staining index clearly correlated with the methylation status of MGMT promoter. In addition, the index correlated with our observational results when nuclear and cytoplasmic staining were assessed in three different fields. Our digital assessment method enabled us to assess uncertain immunopositive samples objectively and quantitatively, which is an important consideration when examining heterogeneous cellular staining. We expect that this method will be useful for assessment of heterogeneous staining with any antibodies.Keywords
This publication has 29 references indexed in Scilit:
- O 6-Methylguanine DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression is correlated with progression-free survival in patients with glioblastomaInternational Journal of Clinical Oncology, 2010
- THE CORRELATION AND PROGNOSTIC SIGNIFICANCE OF MGMT PROMOTER METHYLATION AND MGMT PROTEIN IN GLIOBLASTOMASNeurosurgery, 2009
- Prognostic value of O6-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methodsJournal of Neuro-Oncology, 2009
- Variation of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation in serial samples in glioblastomaJournal of Neuro-Oncology, 2007
- A simplified laboratory validated assay for MGMT promoter hypermethylation analysis of glioma specimens from formalin-fixed paraffin-embedded tissueLaboratory Investigation, 2007
- Quantitative analysis of O6-alkylguanine-DNA alkyltransferase in malignant gliomaMolecular Cancer Therapeutics, 2006
- Targeted Modulation of MGMT: Clinical ImplicationsClinical Cancer Research, 2006
- Prognostic Significance of O6-Methylguanine-DNA Methyltransferase Determined by Promoter Hypermethylation and Immunohistochemical Expression in Anaplastic GliomasClinical Cancer Research, 2005
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- Inactivation of the DNA-Repair GeneMGMTand the Clinical Response of Gliomas to Alkylating AgentsNew England Journal of Medicine, 2000